Value of ¹⁸F-FDG Hybrid PET/MR in Differentiated Thyroid Cancer Patients with Negative ¹³¹I Whole-Body Scan and Elevated Thyroglobulin Levels

References

• Vaccarella S, Franceschi S, Bray F, et al. Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis. N Engl J Med. 2016;375(7):614–617. doi:10.1056/NEJMp160441227532827
   PubMed Web of Science ®Google Scholar
• Kim J, Gosnell JE, Roman SA. Geographic influences in the global rise of thyroid cancer. Nat Rev Endocrinol. 2020;16(1):17–29. doi:10.1038/s41574-019-0263-x31616074
   PubMed Web of Science ®Google Scholar
• Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133. doi:10.1089/thy.2015.002026462967
   PubMed Web of Science ®Google Scholar
• Fatourechi V, Hay ID. Treating the patient with differentiated thyroid cancer with thyroglobulin-positive iodine-131 diagnostic scan-negative metastases: including comments on the role of serum thyroglobulin monitoring in tumor surveillance. Semin Nucl Med. 2000;30(2):107–114. doi:10.1053/nm.2000.460010787191
   PubMed Web of Science ®Google Scholar
• Giovanella L, Ceriani L, De Palma D, et al. Relationship between serum thyroglobulin and 18FDG-PET/CT in 131I-negative differentiated thyroid carcinomas. Head Neck. 2012;34(5):626–631. doi:10.1002/hed.2179121850699
   PubMed Web of Science ®Google Scholar
• Fugazzola L, Elisei R, Fuhrer D, et al. 2019 European thyroid association guidelines for the treatment and follow-up of advanced radioiodine-refractory thyroid cancer. Eur Thyroid J. 2019;8(5):227–245. doi:10.1159/00050222931768334
   PubMed Web of Science ®Google Scholar
• Nascimento C, Borget I, Al Ghuzlan A, et al. Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer. Thyroid. 2015;25(4):437–444. doi:10.1089/thy.2014.032025633259
   PubMed Web of Science ®Google Scholar
• Oh JR, Byun BH, Hong SP, et al. Comparison of 131I whole-body imaging, 131I SPECT/CT, and 18F-FDG PET/CT in the detection of metastatic thyroid cancer. Eur J Nucl Med Mol Imaging. 2011;38(8):1459–1468. doi:10.1007/s00259-011-1809-x21505897
   PubMed Web of Science ®Google Scholar
• Qichang W, Lin B, Gege Z, et al. Diagnostic performance of 18F-FDG-PET/CT in DTC patients with thyroglobulin elevation and negative iodine scintigraphy: a meta-analysis. Eur J Endocrinol. 2019;181(2):93–102. doi:10.1530/eje-19-026131117054
   PubMed Web of Science ®Google Scholar
• Piccardo A, Trimboli P, Foppiani L, et al. PET/CT in thyroid nodule and differentiated thyroid cancer patients. The evidence-based state of the art. Rev Endocr Metab Disord. 2019;20(1):47–64. doi:10.1007/s11154-019-09491-230900067
   PubMed Web of Science ®Google Scholar
• Debois M, Oyen R, Maes F, et al. The contribution of magnetic resonance imaging to the three-dimensional treatment planning of localized prostate cancer. Int J Radiat Oncol Biol Phys. 1999;45(4):857–865. doi:10.1016/s0360-3016(99)00288-610571190
   PubMed Web of Science ®Google Scholar
• Del Grande F, Subhawong T, Weber K, et al. Detection of soft-tissue sarcoma recurrence: added value of functional MR imaging techniques at 3.0 T. Radiology. 2014;271(2):499–511. doi:10.1148/radiol.1313084424495264
   PubMed Web of Science ®Google Scholar
• Platzek I, Beuthien-Baumann B, Schneider M, et al. PET/MRI in head and neck cancer: initial experience. Eur J Nucl Med Mol Imaging. 2013;40(1):6–11. doi:10.1007/s00259-012-2248-z23053322
   PubMed Web of Science ®Google Scholar
• Queiroz MA, Hüllner M, Kuhn F, et al. PET/MRI and PET/CT in follow-up of head and neck cancer patients. Eur J Nucl Med Mol Imaging. 2014;41(6):1066–1075. doi:10.1007/s00259-014-2707-924577950
   PubMed Web of Science ®Google Scholar
• Vrachimis A, Burg MC, Wenning C, et al. [(18)F]FDG PET/CT outperforms [(18)F]FDG PET/MRI in differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2016;43(2):212–220. doi:10.1007/s00259-015-3195-226419851
   PubMed Web of Science ®Google Scholar
• Klain M, Nappi C, Nicolai E, et al. Comparison of simultaneous (18)F-2-[18F] FDG PET/MR and PET/CT in the follow-up of patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2020;47(13):3066–3073. doi:10.1007/s00259-020-04938-032601803
   PubMed Web of Science ®Google Scholar
• Schaarschmidt BM, Grueneisen J, Stebner V, et al. Can integrated 18F-FDG PET/MR replace sentinel lymph node resection in malignant melanoma? Eur J Nucl Med Mol Imaging. 2018;45(12):2093–2102. doi:10.1007/s00259-018-4061-929876618
   PubMed Web of Science ®Google Scholar
• Binse I, Poeppel TD, Ruhlmann M, et al. Imaging with (124)I in differentiated thyroid carcinoma: is PET/MRI superior to PET/CT? Eur J Nucl Med Mol Imaging. 2016;43(6):1011–1017. doi:10.1007/s00259-015-3288-y26686334
   PubMed Web of Science ®Google Scholar
• Biederer J, Ohno Y, Hatabu H, et al. Screening for lung cancer: does MRI have a role? Eur J Radiol. 2017;86:353–360. doi:10.1016/j.ejrad.2016.09.01627665148
   PubMed Web of Science ®Google Scholar
• Quinn B, Dauer Z, Pandit-Taskar N, et al. Radiation dosimetry of 18F-FDG PET/CT: incorporating exam-specific parameters in dose estimates. BMC Med Imaging. 2016;16(1):41. doi:10.1186/s12880-016-0143-y27317478
   PubMed Web of Science ®Google Scholar
• Bertagna F, Bosio G, Biasiotto G, et al. F-18 FDG-PET/CT evaluation of patients with differentiated thyroid cancer with negative I-131 total body scan and high thyroglobulin level. Clin Nucl Med. 2009;34(11):756–761. doi:10.1097/RLU.0b013e3181b7d95c19851169
   PubMed Web of Science ®Google Scholar
• Shammas A, Degirmenci B, Mountz JM, et al. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med. 2007;48(2):221–226.17268018
   PubMed Web of Science ®Google Scholar
• Vural GU, Akkas BE, Ercakmak N, et al. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data. Clin Nucl Med. 2012;37(10):953–959. doi:10.1097/RLU.0b013e31825b205722899202
   PubMed Web of Science ®Google Scholar
• Ciarallo A, Marcus C, Taghipour M, et al. Value of fluorodeoxyglucose PET/computed tomography patient management and outcomes in thyroid cancer. PET Clin. 2015;10(2):265–278. doi:10.1016/j.cpet.2014.12.00925829091
   PubMedGoogle Scholar